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1 These authors contributed equally.Sodium glucose cotransporters (SGLT) actively catalyse carbohydrate transport across cellular mem-
branes. Six of the 12 known SGLT family members have the capacity to bind and/or transport mono-
saccharides (SGLT-1 to 6); of these, all but SGLT-5 have been characterised. Here we demonstrate that
human SGLT-5 is exclusively expressed in the kidney. Four splice variants were detected and the
most abundant SGLT-5-mRNA was functionally characterised. SGLT-5 mediates sodium-dependent
[14C]-a-methyl-D-glucose (AMG) transport that can be inhibited by mannose, fructose, glucose,
and galactose. Uptake studies using demonstrated high capacity transport for mannose and fructose
and, to a lesser extent, glucose, AMG, and galactose. SGLT-5 mediated mannose, fructose and AMG
transport was weakly (lM potency) inhibited by SGLT-2 inhibitors. In summary, we have character-
ised SGLT-5 as a kidney mannose transporter. Further studies are warranted to explore the physio-
logical role of SGLT-5.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction all but SGLT-5 have been characterised. SGLT-1 is mainly expressedDue to their hydrophilic nature, monosaccharides, like glucose,
galactose, mannose, and fructose, require speciﬁc transporters in
order to pass the hydrophobic cell membrane. These are of two
main types: facilitative transporters driven by the concentration
gradient of glucose across the membrane (the glucose transporters
[GLUT (SLC2)] gene family), and active transport proteins that
transport monosaccharides only in the presence of a sodium-dri-
ven electrochemical gradient (the SGLT [SCL5] gene family) [1].
SGLT-mediated sugar transport occurs mainly within the gastroin-
testinal tract and kidney, for absorption of monosaccharides from
food, and reabsorption from the glomerular ﬁltrate back into the
blood, respectively [2].
Six of the 12 known SGLT family members [1] have the capacity
to bind and/or transport monosaccharides (SGLT-1 to 6); of these,chemical Societies. Published by E
pressed sequence tag; GLUT,
ey; hSGLT, human sodium-
hibitory concentration; NGS,
.
im.com (R. Grempler).in the small intestine, and transports glucose and galactose across
the intestinal brush border membrane [1]. Deﬁciency of the
protein in humans causes glucose–galactose malabsorption [1].
SGLT-1 is also expressed in the kidney and contributes to renal
glucose reabsorption [1,3]. SGLT-2 is found predominantly in the
proximal tubules of the kidney and is responsible for the bulk of
renal glucose reabsorption [4]. Mutations in the gene encoding
SGLT-2 lead to familial renal glucosuria, which has no apparent
symptoms and is considered a benign condition [1]. SGLT-3 has
been detected mainly in cholinergic neurons of the submucosal
and myenteric plexi, and in skeletal muscle and is hypothesised
to be a glucose-sensor [5,6]. SGLT-4 has been characterised as a so-
dium-dependent mannose and fructose transporter in the small
intestine and in the kidney [7]. Finally, SGLT-6 is a sodium/myo-
inositol cotransporter expressed in rat intestine and kidney [8,9].
The characterisation of patients with familial renal glucosuria
highlighted the importance of SGLT-2 in renal glucose reabsorp-
tion. In these patients, loss of function mutations in the gene
encoding SGLT-2 result in increased urinary glucose excretion, in
the absence of hyperglycaemia. Patients with this condition have
no apparent symptoms or adverse effects, and have no evidence
of renal dysfunction [10]. Early studies revealed that the non-spe-
ciﬁc SGLT inhibitor, phlorizin, was able to correct hyperglycaemialsevier B.V. All rights reserved.
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type 2 diabetes therapy has since been pursued in the development
of several speciﬁc SGLT-2 inhibitors, including canagliﬂozin, dapa-
gliﬂozin, empagliﬂozin, ipragliﬂozin [11] and tofogliﬂozin [12].
These SGLT-2 inhibitors are highly speciﬁc and efﬁcacious;
however, only approximately 50% inhibition of glucose reabsorp-
tion has been achieved in clinical studies [13]. It is currently not
entirely understood why inhibition of glucose reabsorption is lim-
ited, although the presence of other glucose transporters, e.g. SGLT-
1, in the kidney may contribute. In addition, SGLT-5 is another
transporter of the SGLT family which is abundantly expressed in
the kidney [14–16]. However, the function has not been character-
ised so far.
The aim of this study was to characterise the expression and
function of human SGLT-5, and to determine its potential role in
renal glucose reabsorption.
2. Results
2.1. hSGLT-5 is exclusively expressed in the kidney
In order to identify the tissue distribution of hSGLT-5, real-time
PCR was performed on a panel of 20 human tissue samples with
hSGLT-5-speciﬁc primers. hSGLT-5 was shown to be highly ex-
pressed in human kidney. Low expression of hSGLT-5 was found
in testes and no signiﬁcant ampliﬁcation product was obtained in
the remaining 18 tissues (Fig. 1A). These data are in agreement
with our data generated by Next Generation Sequencing (NGS) of
16 normal human tissues, which found hSGLT-5 expression to be
high in the kidney but absent from all other analysed tissues (data
not shown).
2.2. Alignment of all hSGLT-5 splice variants
To identify the most abundant isoform of hSGLT-5 in human
kidney, NGS and RT-PCR were performed on different human kid-
ney samples. Four splice variants were detected by NGS in human
kidney RNA samples (Fig. 1B). These were conﬁrmed by RT-PCR
using speciﬁc primers (positions are indicated in Fig. 1C) in a panel
of human kidney RNAs. Their identity was conﬁrmed by sequenc-
ing. Isoform 2 (IF2) was the most abundant hSGLT-5 isoform, and
was cloned for further functional characterisation.
2.3. Cloning of hSGLT-5 from human kidney
hSGLT-5 IF2 was cloned from kidney mRNA by RT-PCR into the
pENTR/D-TOPO vector, and conﬁrmed by sequencing. hSGLT-5 IF2
consists of 1980 bp with an open reading frame of 1791 bp, and
was found not to align to the published hSGLT-5 sequence (Gen-
Bank Accession number: NM_152351). The open reading frame is
missing a stretch of 48 bp (1024–1071), which encode 16 amino
acids (328–343) and accounts for the difference in protein size be-
tween the isoform (597 amino acids) and the published sequence
(613 amino acids). Some additional sequence differences were
identiﬁed in positions 154, 1134, 1491, 1823 and 1954, leading
to amino acid differences in positions 365 (Ser->Pro) and 484
(Asn->Asp).
2.4. Functional characterisation of hSGLT-5
To examine the function of hSGLT-5 IF2, a stable inducible HEK
T-REx 293-hSGLT-5 cell line was generated (patent application
pending). Overexpression of hSGLT-5 IF2 mRNA was conﬁrmed
following induction of expression with tetracycline for 24 h andcompared with expression levels in T-REx 293-control cells (Online
Supplementary Fig. 1A). The ability of hSGLT-5 IF2 to transport
monosaccharides in a sodium-dependent manner was evaluated
using [14C]-AMG uptake experiments in the presence or absence
of sodium ions. The observation of sodium-dependent [14C]-AMG
uptake in HEK T-REx 293-hSGLT-5 IF2 cells indicates that hSGLT-
5 is indeed a sodium-dependent monosaccharide transporter
(Online Supplementary Fig. 1B). For comparison, hSGLT-5 IF3 was
cloned and a stable HEK T-REx 293 cell line was generated. Using
the same experimental conditions as for hSGLT-5 IF2, hSGLT-5
IF3 did not show speciﬁc transport of [14C]-AMG (Online Supple-
mentary Fig. 1B).
To evaluate the substrate speciﬁcity of hSGLT-5 IF2, [14C]-AMG
uptake experiments were performed using a range of concentra-
tions from 30 lM to 100 mM of the monosaccharides: mannose,
fructose, glucose and galactose. All monosaccharides were shown
to compete for [14C]-AMG uptake, with mannose and fructose
showing the greatest competitive activity: IC50 values were
1.1 ± 0.4 mM (Ki 0.34 mM) for mannose and 2.2 ± 0.9 mM (Ki
0.84 mM) for fructose. Competition by glucose and galactose was
observed, although at the higher IC50 values of 5.2 ± 2.3 mM and
8.0 ± 4.4 mM, respectively. These results indicate that SGLT-5 has
an afﬁnity for these monosaccharides with a rank order of
mannose > fructose > glucose > galactose (Fig. 2A).
To conﬁrm this ﬁnding, direct monosaccharide uptake experi-
ments were performed using [14C]-labelled monosaccharides in
the absence and presence of sodium chloride or choline chloride
for up to 60 min. The highest uptake was determined for mannose,
followed by fructose. Very low speciﬁc uptake rates were obtained
for both glucose and galactose (Fig. 2B). These results conﬁrm that
mannose and fructose are speciﬁcally transported by hSGLT-5,
with mannose having the highest transport rate. Calculation of
substrate afﬁnities for mannose, fructose and AMG yielded Km val-
ues of 0.45 mM (95% CI 0.28; 0.61), 0.62 mM (95% CI 0.22; 1.0) and
10.1 mM (95% CI 2.0; 18.2), respectively. Vmax values were deter-
mined for mannose to be 2.76 pmol/min/well (95% CI 2.46; 3.06)
for fructose 2.27 pmol/min/well (95% CI 1.80; 2.75) and for AMG
1.63 pmol/min/well (95% CI 0.99; 2.25) (Online Supplementary
Fig. 3).
2.5. Inhibition of hSGLT-5-mediated monosaccharide uptake by SGLT-
2 inhibitors
We determined the ability of C-glucoside (canagliﬂozin,
dapagliﬂozin, and empagliﬂozin) and O-glucoside (phlorizin, rem-
ogliﬂozin and T-1095A) SGLT-2 inhibitors to inhibit SGLT-5-medi-
ated mannose, fructose or AMG uptake. All SGLT-2 inhibitors
exhibited high potency in the range of 1–21 nM for SGLT-2
(Table 1). The compounds inhibited SGLT-5 less potently, in the
range of 0.1–3 lM, albeit with similar Ki values for mannose, fruc-
tose, and AMG (Table 1). This indicates that inhibition is indepen-
dent of the monosaccharide transported. The potency of the
compounds on AMG uptake of SGLT-2 and mannose uptake of
SGLT-5 have been recently published and are shown here again
for comparison (Table 1, column 2 and 3; [17]). Phlorizin and rem-
ogliﬂozin were shown to inhibit mannose uptake at concentrations
ranging from 107 to 104 M (Online Supplementary Fig. 3; data
not shown for other inhibitors). All compounds but remogliﬂozin
had good selectivity for SGLT-2 over SGLT-5, with Ki values in the
range of 740–1500 nM for mannose uptake (a selectivity window
between 200 and 600-fold). In contrast, remogliﬂozin inhibited
SGLT-5 with mean Ki values of 83 nM (fructose uptake), 170 nM
(mannose uptake) and 480 nM (AMG uptake), indicating a selectiv-
ity window of 7 to 40-fold versus SGLT-2 (Table 1).
Fig. 1. Tissue distribution, alternative splice variants, and gene structure for SGLT-5. (A) The expression pattern of SGLT-5 in human tissues was determined by RT-PCR using
SGLT-5-speciﬁc primers in different tissues. (B) PCR products of SGLT-5 splice variants in kidney were analysed on 2% Agarose Gel. Lane 1: kidney (BD, pool of 6 donors); lane
2: kidney (Ambion, 1 donor #); lane 3: small intestine (Ambion, 1 donor #); lane 4: kidney (Clontech, pool of 8 donors $ + #); lane 5: small intestine (Clontech, pool of 11
donors $ + #); lane 6: kidney Clontech (pool of 6 donors $); lane M: DNA size Marker, 100 bp ladder. Four discrete bands were detected, and were extracted and sequenced:
IF1 (933 bp) corresponds to sequence accession number: NM_152351, IF2 (886 bp) to NM_001042450, IF3 (804 bp) to ENST00000395643 and IF4 (777 bp) corresponds to
ENST000004172151. (C) Gene structure of SGLT-5 (Ensembl Gene ENSG00000154025 [SLC5a10]). Exons are displayed in blue boxes. Exon numbers are within the boxes;
exon length is below. Red arrows (>FP2-1 and >RP2-1) indicate the position of PCR primers. Coverage of the exons by NGS-read data of a human kidney sample is in orange;
higher bars indicate higher coverage. The start and the stop signal of the coding sequence is indicated by the green triangle.
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Here we describe the cloning and functional characterisation of
hSGLT-5. We determined that hSGLT-5 has a similar expressionpattern to SGLT-2 [4], being restricted speciﬁcally to the kidney.
Of four splice variants identiﬁed, we cloned two forms IF2 and
IF3. Analysis of cells expressing the two splice variants demon-
strated, that the most abundant variant IF2 was functional in the
Fig. 2. Functional characterisation of SGLT-5. (A) [14C]-AMG uptake by HEK T-REx
293-hSGLT-5 IF2 cells was inhibited by mannose, glucose, fructose and galactose.
Data points are means ± SEM from three independent experiments. (B) Time-
dependent speciﬁc uptake of different monosaccharides by HEK T-REx 293-hSGLT-5
IF2 cells. Speciﬁc uptake was calculated by subtracting the respective monosac-
charide uptake in the presence of choline chloride from the total uptake of the same
monosaccharide in the presence of sodium chloride. Substrate speciﬁcity is highest
for mannose, followed by fructose, with low afﬁnity for glucose, AMG or galactose.
Table 1
Substrate speciﬁcity of SGLT-5 inhibition with SGLT-2 inhibitors.
SGLT SGLT-2 [IC50] SGLT-5 [Ki]
Substrates AMG Mannose Fructose AMG
C-glucosides
Canagliﬂozin 2.7 1500 1000 2000
Dapagliﬂozin 1.2 740 540 570
Empagliﬂozin 3.1 990 910 800
O-glucosides
Phlorizin 21 1300 2700 1700
Remogliﬂozin 12 170 83 480
T-1095A 4.4 990 490 2400
Results are shown as mean IC50 or Ki (nM). Data are derived from at least three
independent experiments.
Fig. 3. Phylogenetic tree of SLC5 family members. A phylogenetic tree was created
using the software tool, Phylip based on a CLUSTALW alignment of the respective
protein sequences. Based on the phylogenetic tree, SGLT-4 represents the closest
SGLT member to SGLT-5.
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Supplementary Fig. 1A/B). The potential reason for an inactive IF3
variant might be the lack of important transmembrane domains
e.g. TM5 and TM6 (Online Supplementary Fig. 4) or in proper tar-
geting and integration of hSGLT-5 IF3 protein into the plasma
membrane. The protein alignment for the four splice variants sug-
gests, that IF1 might also encode for a functional protein (IF1 based
on the abundance of the respective exonic regions and protein se-
quence alignments with the respective predicted protein
sequences (Online Supplementary Fig. 4).SGLT-5 IF2 mRNA was demonstrated to encode functional pro-
tein in monosaccharide uptake studies using [14C]-AMG. Substrate
transport was signiﬁcantly enhanced in the presence of sodium
chloride versus choline chloride, indicating that SGLT-5 is indeed
a sodium-dependent sugar transporter. Furthermore, [14C]-AMG
uptake was competitively inhibited by mannose, fructose, glucose,
and galactose in a concentration-dependent manner, suggesting
that SGLT-5 is capable of binding different sugars. The highest
afﬁnity was for mannose, followed by fructose, then glucose and
galactose. These studies have been strengthened by kinetic mea-
surements calculating Km and Vmax values for mannose, fructose
and AMG, which exhibited the same rank order of afﬁnities as
the initial uptake experiments.
For further electrophysiological characterisation and more de-
tailed kinetic analysis of SGLT-5 the Xenopus laevis oocyte expres-
sion system represents a suitable model system.
Monosaccharide uptake via SGLT-5 was weakly inhibited by all
the tested SGLT-2 inhibitors, and to similar extents for mannose,
fructose and glucose, showing that inhibition of SGLT-5 is sub-
strate-independent. This indicates that these inhibitors are likely
to bind to a common binding site on SGLT-5 and thus, are compet-
itive inhibitors. Mannose is an essential hexose required for glyco-
protein synthesis. Studies performed in rodents and humans
indicate a tight regulation of plasma mannose concentrations in
the range of 100 lM [18]. Mannose uptake and reabsorption has
been well described in animal studies, and our data indicate that
SGLT-5 is one of the speciﬁc transporters that contribute to the reg-
ulation of plasma mannose levels by regulating its reabsorption in
the kidney. Interestingly, in diabetic patients, the plasma concen-
trations of mannose are high, and are positively correlated with
plasma concentration of glucose [19–21]. With the characterisa-
tion of SGLT-5 as a potential renal mannose transporter, the contri-
bution of the kidney in controlling plasma mannose concentrations
and the physiology of its transport could be further underlined.
The lack of speciﬁc antibodies for SGLT-5 limit our ability to
determine the exact localisation of the protein within the kidney’s
tubular system and thereby, its potential physiological role. Based
on sequence homology, SGLT-4 is the closest SGLT family member
to SGLT-5 (Fig. 3) and has also recently been characterised as a
mannose transporter [7,15,16]. Interestingly, whereas SGLT-4 is
predominantly expressed in the intestine, SGLT-5 is exclusively
found in the kidney, suggesting a complementary role for the
two transporters in regulating mannose absorption and reabsorp-
tion, respectively.
SGLT-5 may also participate in controlling reabsorption of glu-
cose, depending on the concentration of sugar in the kidney tu-
bules. However, our data indicate that the role of SGLT-5 in
glucose reabsorption is minor in comparison to SGLT-2 and
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blockade may be the increased excretion of fructose. As increased
intake of fructose has been associated with insulin-resistance and
hepatic steatosis, an enhanced excretion of fructose may have
beneﬁcial effects on these early signs of diabetes [22,23]. However,
the individual contribution of SGLT-5 in renal fructose reabsorp-
tion will need to be further evaluated.
The low selectivity of remogliﬂozin for SGLT-5, over SGLT-2,
suggests that this agent may be a useful pharmacological tool for
the study of SGLT-5-mediated monosaccharide reabsorption in
addition to its action on SGLT-2 in the kidney.
Pharmacological inhibition of SGLT-5 could potentially increase
sodium excretion with potential consequences on blood pressure
lowering, an effect seen with SGLT-2 inhibitors in clinical studies
[24–26]. However, it has to be considered that mannose plasma
concentrations are in the low micromolar range and therefore
the amount of sodium that is co-transported by SGLT-5 may be
much lower compared to SGLT-2.
In conclusion, we have characterised hSGLT-5 as a kidney-spe-
ciﬁc, sodium-dependent mannose and fructose co-transporter.
Further investigation of the physiological contribution of SGLT-5
to renal monosaccharide reabsorption is warranted.
4. Experimental procedures
4.1. Chemicals
All chemicals were of analytical grade and purchased from Sig-
ma–Aldrich (Gillingham, UK), unless indicated otherwise. Canagli-
ﬂozin, dapagliﬂozin, empagliﬂozin, remogliﬂozin, and T-1095A
were synthesised at Boehringer Ingelheim Pharma GmbH & Co.KG,
Biberach, Germany.
4.2. Expression of hSGLT-5 mRNA in human tissues
Expression of hSGLT-5 was determined using a human tissue
panel (Ambion, Austin, TX, USA). In brief, 100 ng of mRNA was re-
verse-transcribed into cDNA using the SuperScript™ First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA). Quan-
titative real-time PCR was performed with the ABI Prism 7000 Se-
quence Detection System (Applied Biosystems, Foster City, CA,
USA), using primers speciﬁc for hSGLT-5 (forward primer: 50-GAT
GAC CTT TGG CCT GAC CAT-30; reverse primer: 50-GTC CCG GGC
TGA CAG TGA T-30; MWG Biotech, Ebersberg, Germany). Expres-
sion of GAPDH was used as an endogenous control. Quantitative
expression of hSGLT-5 was determined using a standard curve.
4.3. Detection of hSGLT-5 splice variants
For the detection of splice variants in human kidney via PCR,
Human Kidney Total RNAs were purchased from Clontech, BD
Biosciences (pool of 6 donors), and Ambion (1 male donor). Addi-
tionally, RNA from human small intestine (Ambion) was pur-
chased. RNA templates were reversely transcribed into cDNA and
ampliﬁed using a standard PCR protocol. For the First-Strand cDNA
synthesis, the Reverse Transcriptase Super Script II (Invitrogen)
was used. Synthesised cDNA was used as a template in subsequent
PCR. Primer sequences used were: forward primer 2-1: 50-TAC GCG
GGG GCT CTG TTT GT-30 and reverse primer 2-1: 50-GGG AGC TGG
TCA CTG ACT GCA T-30. The resulting PCR products were loaded on
2% Agarose Gel. PCR fragments were extracted using the Qiaquick
Gel Extraction Kit (Qiagen) and puriﬁed fragments were sequenced
by Sequiserve (Sequiserve GmbH, Germany). For NGS, Human Kid-
ney Total RNA was purchased from Clontech (CATALOG No.
636529). Preparation of libraries and respective sequencing was
performed as previously described [27].4.4. Cloning of SGLT-5 from human kidney
The most abundant SGLT-5 isoform (IF2) was cloned from kid-
ney mRNA (Clontech BD Biosciences, Palo Alto, CA, USA) by RT-
PCR. A transcript of 1980 kb encoding a protein of 597 amino acids
was ampliﬁed using primers based on sequences from GenBank
(accession number: NM_001042450; forward primer: 50-CAC CGC
CAT GGC CGC CAA CTC CA-30 and reverse primer 50-TCA GGC
GAA GTA GGC ATA AAA GAA TAT GTT GAC-30). The ampliﬁcation
product was cloned into the pcDNA3.1/V5-His-TOPO plasmid.
The open reading frame (1791 bp) was subsequently cloned into
the pENTR/D-TOPO Plasmid (Invitrogen, Carlsbad, CA, USA) using
the TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA), and li-
gated into the pT-REx-Dest30 Plasmid via the clonase reaction.
The insert was sequenced and aligned to the GenBank hSGLT-5
sequence.
4.5. Generation of stable inducible HEK T-REx 293-hSGLT-5 cells
The pT-REx-Dest30-hSGLT-5 IF2 plasmid was transfected into
HEK T-REx 293 cells (Invitrogen, Carlsbad, CA, US) using Lipofect-
amine™ 2000 (Invitrogen) according to the manufacturer’s proto-
col. Stable expression was obtained upon selection with 600 lg/
mL geneticin and clones were selected by limited dilution. Clones
were characterised for SGLT-5 expression and functionality by per-
forming [14C]-AMG uptake experiments. One functional clone (HEK
T-REx 293-hSGLT-5 IF2) was used for all subsequent experiments
(patent application pending). The cells were cultivated in Dub-
lecco’s modiﬁed eagle medium (DMEM) containing 10% foetal calf
serum (FCS), 600 lg/mL geneticin and 5 lg/mL blasticidin.
4.6. [14C]-monosaccharide uptake experiments
HEK T-REx 293-hSGLT-5 IF2 cells (30,000 cells per well) were
seeded in white poly-D-lysine-coated 96-well plates, and SGLT-5
expression was induced for 24 h with 1 lg/mL tetracycline. For
the assay, cells were washed twice with 250 lL pre-treatment buf-
fer (140 mM choline chloride in basal buffer [10 mM HEPES;
5.4 mM KCl; 2.8 mM CaCl2⁄2H2O; 1.2 mM MgSO4⁄7H2O; 0.1%
bovine serum albumin (BSA), pH 7.4]) and incubated in 200 lL
pre-treatment buffer for 25 min at 37 C. Pre-treatment buffer
was removed and 200 lL uptake buffer was added to the cells
(140 mM NaCl in basal buffer plus 50 lM monosaccharide [glu-
cose, fructose, mannose, galactose or AMG] including 0.6 lCi of
the same [14C]-labelled monosaccharide [glucose, fructose,
mannose, galactose or AMG, respectively], (Hartmann Analytics,
Mannheim, Germany) and 10 lM Cytochalasin B). After incubation
for 5, 10, 30 and 60 min at 37 C, the cells were washed three times
with 300 lL phosphate-buffered saline (PBS, Cambrex, Verviers,
Belgium) and then lysed in 0.1 N NaOH with intermittent shaking
for 5 min. The lysate was mixed with 200 lL MikroScint 40 Scintil-
lator, shaken for 15 min and counted for radioactivity in the Top-
Count NXT (Canberra Packard, Schwadorf, Austria). Speciﬁc
monosaccharide uptake was determined by subtracting non-spe-
ciﬁc uptake of each monosaccharide in the presence of choline
chloride from total uptake of the samemonosaccharide in the pres-
ence of sodium chloride.
4.7. [14C]-monosaccharide uptake inhibition by SGLT-2 inhibitors
HEK T-REx 293-hSGLT-5 IF2 cells were pre-incubated in 200 lL
uptake buffer (10 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 2.8 mM
CaCl2, 1.2 mM MgCl2, 50 lg/mL Gentamycin, 0.1% BSA) for
25 min at 37 C. 10 lM Cytochalasin B and inhibitors were added
at different concentrations 15 min before the initiation of the up-
take experiment. The uptake reaction was started by the addition
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respective, un-labelled monosaccharide. After incubation for
60 min at 37 C, cells were washed three times with 300 lL PBS
and lysed in 0.1 N NaOH by intermittent shaking for 5 min. The
lysate was mixed with 200 lL MikroScint 40 Scintillator, shaken
for 15 min and counted for radioactivity in the TopCount NXT. A
dose–response curve was ﬁtted to an empirical four-parameter
model using XL Fit (IDBS, Guildford, UK) to determine IC50 values.
4.8. [14C]-AMG uptake – competition by monosaccharides
For the competition experiment with [14C]-AMG (Fig. 2A), cold
AMG was used at a concentration of 1 mM. Dose-dependent inhi-
bition of [14C]-AMG uptake by mannose, fructose, glucose and
galactose was tested at concentrations ranging from 30 lM to
100 mM.
4.9. Calculation of kinetic parameters and Inhibitor constants (Ki)
Data from kinetic experiments were used to calculate Km- and
Vmax-values for mannose, fructose and AMG by using non-linear
regression using Michaelis–Menten Algorithm Y = Vmax ⁄ X/
(Km + X) in GraphPad Prism Software (San Diego, CA). Y is the up-
take of respective monosaccharide in pmol/min/well and X is the
monosaccharide concentration used in mmol/l. Km is expressed
in mmol/l and Vmax is expressed in pmol/min/well. GraphPad Prism
was also used to calculate the 95% Conﬁdence Intervals (95% CI) of
the mean and kinetic values are given with the lower and upper
limit of the CI.
Inhibitor constants Ki were calculated using the Cheng–Prusoff
equation: Ki = IC50/(1+[S]/Km) in GraphPad Prism.
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